Company intelligence / Profile preview

Roivios

Nassau, Bahamas

Ownership: Private
Development stage: Other

Overview

Preclinical and feasibility clinical studies of the JuxtaFlow Renal Assist Device (RAD) demonstrated positive results, including preservation of kidney function and reduced hypoxia-induced damage during acute stress, with the device now progressing toward a pivotal trial and FDA breakthrough designation received.[1][5][6]

Therapeutic areas: Nephrology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Caresyntax

Beyond the preview

Go deeper on Roivios.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Roivios.

Explore the full profile